Prostate Adenocarcinoma

About
Mappings

OncoTree: Prostate Adenocarcinoma (coding:oncotree:PRAD)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organizations Biomarkers Cancer types Therapies
EMA (1) FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
EMA (1) FDA (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
EMA (1) FDA (2) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
EMA (1) FDA (2) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
EMA (1) FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Olaparib
EMA (1) FDA (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Olaparib
EMA (1) FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Olaparib
EMA (1) FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) ATM pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) ATM oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BARD1 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BARD1 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BRIP1 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BRIP1 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CDK12 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CDK12 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CHEK1 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CHEK1 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CHEK2 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CHEK2 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) FANCL pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) FANCL oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) PALB2 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) PALB2 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD51B pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD51B oncogenic variants Prostate Adenocarcinoma Talazoparib
FDA (1) RAD51C pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD51C oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD51D pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD51D oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD54L pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD54L oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Rucaparib
FDA (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Rucaparib
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Rucaparib
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Rucaparib
FDA (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) ATM pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) ATM oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) ATR oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) CDK12 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) ATR pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) FANCA oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) CHEK2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) CHEK2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) FANCA pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) MLH1 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) PALB2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) PALB2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) MLH1 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) MRE11 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) RAD51C pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) RAD51C oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) MRE11 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) NBN oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) NBN pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) CDK12 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
EMA (2) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone
EMA (2) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone
EMA (2) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone
EMA (2) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone